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Abstract
Background: Nociceptive and neuropathic pain occurs as part of the disease process after traumatic brain injury (TBI) in
humans. Central and peripheral inflammation, a major secondary injury process initiated by the traumatic brain injury event,
has been implicated in the potentiation of peripheral nociceptive pain. We hypothesized that the inflammatory response to
diffuse traumatic brain injury potentiates persistent pain through prolonged immune dysregulation.
Results: To test this, adult, male C57BL/6 mice were subjected to midline fluid percussion brain injury or to sham procedure. One cohort of mice was analyzed for inflammation-related cytokine levels in cortical biopsies and serum along an acute
time course. In a second cohort, peripheral inflammation was induced seven days after surgery/injury with an intraplantar
injection of carrageenan. This was followed by measurement of mechanical hyperalgesia, glial fibrillary acidic protein and Iba1
immunohistochemical analysis of neuroinflammation in the brain, and flow cytometric analysis of T-cell differentiation in
mucosal lymph. Traumatic brain injury increased interleukin-6 and chemokine ligand 1 levels in the cortex and serum that
peaked within 1–9 h and then resolved. Intraplantar carrageenan produced mechanical hyperalgesia that was potentiated by
traumatic brain injury. Further, mucosal T cells from brain-injured mice showed a distinct deficiency in the ability to differentiate into inflammation-suppressing regulatory T cells (Tregs).
Conclusions: We conclude that traumatic brain injury increased the inflammatory pain associated with cutaneous inflammation by contributing to systemic immune dysregulation. Regulatory T cells are immune suppressors and failure of T cells to
differentiate into regulatory T cells leads to unregulated cytokine production which may contribute to the potentiation of
peripheral pain through the excitation of peripheral sensory neurons. In addition, regulatory T cells are identified as a
potential target for therapeutic rebalancing of peripheral immune homeostasis to improve functional outcome and decrease
the incidence of peripheral inflammatory pain following traumatic brain injury.
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Background
Traumatic brain injury (TBI) is a major cause of death
and disability throughout the world, with few treatments
for those who suﬀer from subsequent lifelong
neurological symptoms. The somatic symptoms of TBI
include sensory hypersensitivity and persistent pain,
which encompasses headache, nociceptive pain, and
neuropathic pain, the latter of which is deﬁned as pain
initiated or caused by a lesion or disease of the somatosensory system. Although epidemiological data support
the occurrence of pain as a secondary complication of
TBI,1–5 only a limited description of postinjury pain in
experimental models is available,6 with even fewer investigations of underlying mechanisms.7
For the intact nervous system, a stimulus of suﬃcient
magnitude to evoke the sensation of pain can directly
damage tissue and this serves an adaptive function;8 however, under pathological conditions, sensitization can
occur resulting in maladaptive pain states.9,10 In these
instances, tissue injury causes changes in neuronal activation of pain pathways, thus increasing the excitability of
central nervous system (CNS) neurons.9–11 Together,
these neuronal changes result in sensitization associated
with evoked hypersensitivity to typically painful (hyperalgesia) and nonpainful (allodynia) stimuli.9,12,13
TBI results in neuronal cell death, ischemia, hemorrhage, and the disruption of the blood–brain barrier
(BBB). These primary insults initiate a secondary
injury response of cellular and molecular cascades
including central inﬂammation and the production of
cytokines.14 Furthermore, TBI-induced disruption of
the BBB allows passage of inﬂammatory cytokines out
of the injured brain, thereby initiating a systemic
immune response.15 Together, these central and peripheral immune responses contribute to microglia activation, astrocytosis, leukocytic inﬁltration,16 and the
secretion of immunological factors and pronociceptive
mediators (e.g. cytokines). The overall increase in inﬂammation-mediating cytokines and chemokines establish
neuronal hypersensitivity,10,11,13,17 which we hypothesize
induces hyperalgesia.9–11,13,17,18 In addition, the persistent inﬂammatory signaling maintain immune cells in an
activated state, such that they are primed for future challenges and insults. This primed proﬁle may set the stage
for hyperactivity to challenges including a peripheral
immune response (for review, see Witcher et al.).19
The composition of cytokines and regulatory factors
in the surrounding environment determine the functional
lineage in mature T cells as either proinﬂammatory eﬀector helper T cells (Th) or anti-inﬂammatory T-regulatory
cells (Tregs).20 Tregs contribute to maintaining immune
cell homeostasis21 by controlling not only the speciﬁcity
and intensity of eﬀector T cell function but also the
proinﬂammatory reactivity of innate immune cells (see
Figure 1).22,23 For example, Tregs originating in the
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thymus can prevent autoimmune reactions, while
adaptive (induced) Tregs have a more prominent antiinﬂammatory activity and are instrumental in the control
of inﬂammation-associated immune reactions.24–26 In
this context, previous studies suggested that Tregs
contribute to the resolution of brain-injury-induced
inﬂammation.12 Experimentally, mouse Tregs can be
identiﬁed by the expression of the forkhead family transcription factor (Foxp3) in combination with the high
expression of the interleukin 2 (IL-2) receptor alpha
subunit, CD25.
Here, we hypothesize that TBI potentiates hyperalgesia by dysregulating the T cell response and increasing
the susceptibility (priming) of the systemic immune
system to respond to a secondary challenge or insult.
Following midline ﬂuid percussion injury (FPI), inﬂammation and hyperalgesia were tested after carrageenan
injection in the hind paw. The central immune response
to diﬀuse TBI was assessed by microglia and astrocyte0
morphology and inﬂammatory mediator levels in the
cortex. The peripheral immune response was assayed
by inﬂammatory mediator levels in the serum. Finally,
the response of mucosal lymph node T cells to all-trans
retinoic acid (ATRA), a potent inducer of Tregs, was
tested to evaluate T cell diﬀerentiation following TBI.
Results indicated that diﬀuse brain injury increased
inﬂammatory pain associated with cutaneous inﬂammation by priming the systemic immune system toward a
proinﬂammatory response. Furthermore, T cell dysfunction may have contributed to unresolved peripheral
inﬂammation which potentiated mechanical hyperalgesia
(see Figure 1).

Methods
Animals
Male C57BL/6 mice (Harlan Laboratories, Inc.,
Indianapolis, IN) were used for all experiments. The animals were housed at a constant temperature (23 C 
2 C) with food and water available ad libitum according
to the Association for Assessment and Accreditation of
Laboratory Animal Care International. Animals were
acclimated to their environment following shipment for
at least three days prior to any experiments. After surgery, postoperative care included daily evaluation and
documentation of the health status of each animal with
a physical examination. Animal care and procedures
were approved by the University of Kentucky
Institutional Animal Care and Use Committee.

Midline fluid percussion injury
Adult male C57BL/6 mice (20–24 g) were subjected to
midline ﬂuid percussion injury (mFPI) consistent with
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Figure 1. Proposed mechanistic link between unregulated peripheral inflammation and inflammatory hyperalgesia following TBI. (a) In
uninjured sham mice, carrageenan injection into the paw (1) initiates a pro-inflammatory immune response that is homeostatically
regulated (2). Anti-inflammatory actions of Tregs suppress inflammation and result in a normal response to painful stimuli in the von Frey
filament test (3). (b) Diffuse brain injury induces systemic immune dysregulation, specifically through deficiencies in T cell proliferation and
differentiation of Tregs (1). Carrageenan injection into the paw (2) initiates an inflammatory response that is unregulated in the absence of
Tregs (3). Resulting proinflammatory cytokines cause aberrant excitation of sensory neurons (4), potentiating hyperalgesia in the von Frey
filament test (5).
TBI: traumatic brain injury; Tregs: regulatory T cells.

methods previously described.27 Mice were anesthetized
using 5% isoﬂurane in 100% oxygen for 5 min and
the head of the animal was placed in a stereotaxic
frame with continuously delivered isoﬂurane at 2.5%
via nosecone. While anesthetized, body temperature
was maintained using a Deltaphase isothermal heating
pad (Braintree Scientiﬁc Inc., Braintree, MA). A midline
incision was made exposing bregma and lambda, and
fascia was removed from the surface of the skull. A
midline craniotomy was performed via trephination

(3 mm outer diameter) between the bregma and lambda
joints where a modiﬁed Luer lock hub was aﬃxed using
cyanoacrylate gel and methyl-methacrylate (Hygenic
Corp., Akron, OH) over the exposed dura. The injury
cap was closed using a Luer lock cap and animals were
placed in a heated recovery cage and monitored until
ambulatory before being returned to their cage.
For injury induction 24 hours postsurgery, animals
were reanesthetized with 5% isoﬂurane delivered for
5 min. The cap was removed from the injury-hub
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assembly and the craniotomy was visually inspected
through the hub. The hub was then ﬁlled with normal
saline and attached to the male end of the ﬂuid percussion device (Custom Design and Fabrication, Virginia
Commonwealth University, Richmond, VA). Pendulum
release resulted in a diﬀuse brain injury (average of
1.4 atm). Sham animals were attached to and removed
from the ﬂuid percussion device without dropping the
pendulum. Animals were monitored for righting reﬂex
recovery time and for the presence of a forearm fencing response as a metric of injury severity.28 The
righting reﬂex time is the total time from the initial
impact until the animal spontaneously rights itself. The
fencing response is a tonic posturing characterized by
extension and ﬂexion of opposite arms that has been
validated as an overt indicator of injury severity.28
The injury hub was removed and the brain was
inspected for uniform herniation and integrity of the
dura. After spontaneously righting, animals were
placed in a heated recovery cage and monitored until
ambulatory before being returned to their cage
(approximately 5 to 15 min).

Tissue preparation and cytokine measurement
At selected time points (1, 3, 9, 12, 24, 48, and 168 h)
postsurgery, mice were given an overdose of sodium
pentobarbital and transcardially perfused with
phosphate-buﬀered saline (PBS) after cardiac blood
draws. Mice were decapitated and the brains were dissected on ice and samples were snap frozen in liquid
nitrogen then stored at 80 C until used. The protein
levels of a panel of inﬂammatory cytokines were measured in the cortex and serum by Meso Scale
Discovery (MSD) multiplex immunoassay (sector
imager 2400, Meso Scale Discovery; Gaithersburg,
MD) as previously described.29,30 A PBS soluble
brain homogenate was prepared from cortical tissue
using a high shear homogenizer (Omni TH115), in a
1:10 (w/v) of ice-cold, freshly prepared lysis buﬀer consisting of 1 mg/ml leupeptin, 1 mM phenylmethylsulfonyl ﬂuoride, and 1 mM ethylenediaminetetraacetic acid.
The cortical homogenate was centrifuged at 12,000 x g
for 20 min at 4 C, and supernatants were collected.
MSD custom multiplex high-sensitivity ELISA kits
were used according to the manufacturer’s instructions
with minor modiﬁcations. Brieﬂy, 25ml of undiluted
serum or 100 mg of protein of the PBS soluble brain
supernatant was loaded per well of the MSD plate.
The sample was incubated at 4 C for 14 h. All incubation steps were done using an Eppendorf MixMate
at 1000 rpm. Brain samples were normalized to the
total amount of protein in the sample loaded as determined by BCA Protein Assay (Thermo Scientiﬁc,
Waltham, MA, USA).
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Mechanical hyperalgesia testing
All testing began between 10:00 am and 12:00 pm in a temperature- and light-controlled room. Mice were acclimated for 30–60 min in the testing environment within a
custom rectangular plastic box (15  4  4 cm; three white
opaque walls and one clear wall) on a raised metal mesh
platform. Baseline testing was conducted at seven days
after TBI, and then at 2 and 4 h after carrageenan injection
(see below for methods). To evaluate mechanical hypersensitivity (hyperalgesia), we used a logarithmically
increasing set of eight von Frey ﬁlaments (Stoelting,
Illinois), ranging in gram force from 0.007 to 6.0 g, as previously described.31 These were applied perpendicular to
the ventral-medial hind paw surface with suﬃcient force to
cause a slight bending of the ﬁlament. A positive response
was characterized as a rapid withdrawal of the paw away
from the stimulus ﬁlament within 4 s. Using the up-down
statistical method (Chaplan et al., 1994), the 50% withdrawal mechanical threshold scores were calculated for
each mouse. We then calculated the carrageenan-induced
change in mechanical threshold as the maximum possible
eﬀect (MPE) for each individual mouse with the following
formula: MPE ¼ ([50% threshold after carrageenan 
baseline 50% threshold]/baseline 50% threshold)  100.

Carrageenan model of inflammatory pain
At seven days postinjury, a baseline assessment of mechanical sensitivity was obtained prior to mice being lightly
restrained and injected with low-dose carrageenan (0.2%
in 5 ml 0.9% saline) into the intraplantar surface (ventralmedial) of the left hind paw.32 To control for needle
puncture and injectate volume, a mock procedure consisted of an intraplantar injection of saline (5 ml, 0.9%).

Tissue preparation for histology
At seven days postinjury or sham operation, mice used
for mechanical threshold testing were given an overdose
of sodium pentobarbital and transcardially perfused with
4% paraformaldehyde after a PBS ﬂush. Brains were
removed and placed in 4% paraformaldehyde overnight
then immersed in serial dilutions (10%, 20%, and 30%)
of sucrose for 24 h each. The brains were removed from
sucrose and frozen at 20 C. After freezing, brains were
sectioned on a cryostat in the coronal plane at 20 mm,
mounted onto glass slides, and stored at 80 C.

Immunofluorescence
Slides with brain sections were removed from 80 C,
placed in an oven at 60 C for approximately 4 h
and then rinsed three times for 5 min each in PBS.
Next, the slides were blocked in 4% v/v donkey serum
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in PBS. Primary antibodies were added to 1% blocking
solution, rabbit anti-ionized calcium binding adaptor
molecule 1 (Iba-1; 1:2000, WAKO, cat# 019919741) or
rabbit anti-glial ﬁbrillary acidic protein (1:5000, DAKO,
cat# Z033429-2) and stored at 4 C overnight. Slides were
rinsed three times in PBS and the secondary antibody
(donkey anti-rabbit Alexa Fluor 488 or 594) was added
and slides were incubated on a rocker at room temperature
for 1 h. Finally, slides were rinsed in deionized water and
coverslipped with antifade medium (Fluoromount G;
Southern Biotech, Birmingham, AL). The cortex was
examined for microglia and astrocyte activation in
response to brain injury using a Zeiss LSM 710 laser scanning confocal microscope with attached digital camera.

Induction of regulatory T cells
Mucosal lymph nodes were removed postmortem from
brain-injured (n ¼ 4) and sham (n ¼ 4) mice seven days
postinjury. Lymph node cells were then isolated via mechanical disruption and centrifugation. Cells were resuspended at a density of 2  106/mL in iTreg medium:
RPMI-1640 GlutaMAX (Invitrogen) supplemented with
10% fetal bovine serum (Gibco), 50 mM b-mercaptoethanol
(Sigma-Aldrich), 2 ng/mL TGF-b (eBioscience), and
1 ng/mL IL-2 (eBioscience). 500 mL (1  106 cells) were
incubated in 48-well tissue culture plates precoated
with 500 ng/mL a-CD3 (clone: 145–2C11, Bio X Cell)
for six days at 37 C/5% CO2. Half of the medium was
replaced on day 3 of culture. When indicated, 1 mM
ATRA (Sigma-Aldrich, St. Louis, MO) or 0.5 mg/mL
soluble a-CD28 (clone: 37.51, eBioscience, San Diego,
CA) was added to the culture medium.

Flow cytometric analysis of Treg development
Cells were stained using Foxp3 Staining Buﬀer Set and
the following antibodies from eBioscience: a-CD25-AF488, a-CTLA-4-PE, a-CD4-PE-Cy5, and a-CD62L-PECy5 or from Miltenyi: Foxp3-APC. Some lymphocytes
were labeled with 5 mM carboxyﬂuorescein succinimidyl
ester (CFSE; Invitrogen, Carlsbad, CA) per million cells
for 3 min at room temperature. Fluorescent lymph node
cells were assessed on a LSRII (BD Biosciences, San
Jose, CA, USA) ﬂow cytometer and analyzed with
FlowJo software (Tree Star Inc., Ashland, OR, USA).
Tregs (CD25hi/Foxp3hi) cells are reported as a percentage of the CD4þ cells with side and forward scatter proﬁles consistent with live lymphocytes (cells were collected
as described earlier; sham n ¼ 4, injury sham ¼ 4).

Statistical analysis
Data are shown as mean  SEM and analyzed using statistical software (GraphPad-Prism 6). Diﬀerences in
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mechanical threshold were determined using a repeated
measures analysis of variance (ANOVA) followed by a
Sidak’s multiple comparisons test. Cortical cytokine
levels were determined with a one-way ANOVA
followed by Dunnett’s multiple comparison test.
Statistical signiﬁcance was assigned for p < .05.

Results
Diffuse TBI potentiated mechanical hyperalgesia
At seven days postinjury, mechanical pain thresholds in
the hind paws were tested to establish a baseline (preinjection) response for each animal. Baseline mechanical
sensory thresholds were comparable in uninjured
(n ¼ 4) and brain-injured (n ¼ 4) mice (t6 ¼ 0.1549,
p ¼ 0.8820; data not shown). To test the hypothesis
that diﬀuse TBI potentiates inﬂammatory pain,
carrageenan was injected in the hind paw. At 2 and 4 h
postinjection, mechanical threshold was decreased
in brain-injured, compared to uninjured sham mice,
F(1, 6) ¼ 11.90, p ¼ 0.0136; Figure 2(a). Decreases were
also observed in the noninjected paw, but this failed to
reach signiﬁcance, F(1, 6) ¼ 2.927, p ¼ .1380; Figure 2(b).

Diffuse TBI activated central and peripheral
immune responses
IBA-1 immunohistochemistry identiﬁed microglia in the
uninjured and brain-injured cortex. As previously
reported by our group in the mFPI model, microglia in
uninjured brain remain predominantly in a ramiﬁed
(unactivated) morphology33,34 (Figure 3a). In the diﬀuse
brain-injured cortex, microglia showed activated
(rounded cell body with thickened processes) and
amoeboid morphologies (Figure 3b), consistent with previous reports.33,34 In addition, activated astrocytes were
found in brain-injured cortex (Figure 3d), indicated by
hypertrophy, thickened processes, and enhanced expression of glial ﬁbrillary acidic protein (GFAP), compared
to sham (Figure 3c).
With a multiplex high-sensitivity ELISA, we found
that diﬀuse brain injury led to rapid elevation in cortical
protein levels of inﬂammatory cytokines (Figure 4a–d).
Cortical IL-6 levels were signiﬁcantly diﬀerent between
the uninjured sham and the brain injury time points, F(7,
19) ¼ 2.779, p ¼ 0.0361; Figure 4a), where Dunnett’s multiple comparison test indicated a signiﬁcant increase in
IL-6 at 9 h postinjury compared to uninjured sham.
Cortical chemokine ligand 1 (CXCL1) levels were signiﬁcantly diﬀerent between uninjured sham and the brain
injury time points, F(7, 19) ¼ 1.617, p < 0.0001;
Figure 4b), where Dunnett’s multiple comparison test
indicated a signiﬁcant increase in CXCL1 at 1, 3, and
9 h postinjury compared to uninjured sham. While there
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Figure 2. TBI potentiated mechanical hyperalgesia in response to a peripheral immune challenge. (a and b) Mechanical hyperalgesia was
assessed at seven days post-TBI (baseline; dotted line) and then 2 h and 4 h following carrageenan injection in the paw. Graphs depict the
mechanical stimulation required to elicit a withdrawal response after carrageenan injection, as a percent of baseline, where values below 100%
indicate increased sensitivity. Measurements were taken for the (a) injected and (b) noninjected paw (n ¼ 4 per group, mean  SEM, *p < 0.05).
TBI: traumatic brain injury.

Figure 3. TBI activated microglia and astrocytes in the cortex. Seven days postinjury, cortical sections were immunostained for microglia
and astrocyte activation using antibodies against (a and b) Iba-1 and (c and d) GFAP, respectively. (a) Highly ramified microglia from sham
mice sharply contrasted with (b) activated microglia found following TBI. Increased process size was also noted among astrocytes from
brain-injured mice (d) compared with uninjured sham (c). (40  magnification, scale bars ¼ 20 mm).
TBI: traumatic brain injury; GFAP: glial fibrillary acidic protein.

were injury-induced, immediate increases in cortical
protein levels of TNF-a, F(7, 19) ¼ 1.145, p ¼ 0.3624;
Figure 4c, and IL-10, F(7, 19) ¼ 1.043, p ¼ 0.4351;
Figure 4d, relative to sham levels, the increases did not
reach statistical signiﬁcance.

As the BBB is permeable after mFPI,35 the potential
exists for inﬂammatory molecules produced at the central injury site to act at distal sites in the periphery. To
evaluate brain to blood transfer of signal, we repeated
and expanded the cytokine array using serum samples.
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Figure 4. TBI initiated a central and peripheral inflammatory response. Cortical cytokine and chemokine levels were measured by
multiplex ELISA following TBI (a-d). Acute increases in proinflammatory (a) IL-6 and (b) CXCL1 were significant in comparison to
uninjured sham levels (n ¼ 3–5, mean  SEM). Serum cytokine and chemokine levels were measured for nine chemokine and cytokine
analytes at seven time points following diffuse TBI (e). Proinflammatory CXCL1 and IL-6 were significantly elevated compared to sham
during the acute phase following injury (n ¼ 3–5). Although the levels for the remaining molecules changed with respect to sham, the
differences were not significant in comparison to sham. Color gradations indicate the protein levels compared to sham, where reds are
increased levels and blues are decreased levels.
TBI: traumatic brain injury; ELISA: enzyme-linked immunosorbent assay; IL6: interleukin 6; CXCL1: chemokine ligand 1.

Serum levels of IL-6, F(7, 17) ¼ 3.374, p ¼ 0.019, were
signiﬁcantly diﬀerent over time postinjury (Figure 4e).
Dunnett’s multiple comparison test indicated signiﬁcant
increases in serum IL-6 levels at 1 h postinjury compared
to uninjured sham. CXCL1 was signiﬁcantly diﬀerent
over time postinjury, F(7, 17) ¼ 12.190, p < 0.0001,
Figure 4e). IL-4, F(7, 18) ¼ 1.522, p ¼ 0.2225, and
IL-10, F(7, 18) ¼ 2.111, p ¼ 0.0956, levels remained
increased in serum from brain-injured animals compared
to uninjured shams up to one week postinjury, however,
these increases did not reach statistical signiﬁcance.

Diffuse TBI dysregulated induced Treg development
Mesenteric lymph node (MLN) T cells localized into the
mucosal immune system showed dysregulated Treg differentiation and proliferation in response to ATRA, a
Treg stimulating factor, in brain-injured, but not sham
mice (Figure 5). As expected, MLN T cells from uninjured shams (top left, Figure 5a) and brain-injured
(bottom left, Figure 5a) mice cultured with dimethyl sulfoxide (DMSO) vehicle showed an activated phenotype
(primarily CD25hi/Foxp3lo), with minimal Treg diﬀerentiation. MLN T cells from uninjured shams cultured with

ATRA, a factor which induces Treg diﬀerentiation and
mucosal homing, showed increased Treg diﬀerentiation
(primarily CD25hi/Foxp3hi; top right, Figure 5a). In contrast, MLN T cells from brain-injured mice cultured with
ATRA showed minimal T cell activation and less than
1% Treg diﬀerentiation (bottom right, Figure 5(a)).
T cells were labeled with CFSE, a ﬂuorescent dye, to
ascertain the capacity for cell proliferation. The CFSE
proliferation assay indicated lymph cells from uninjured
shams demonstrated near maximal proliferation capacity
when cultured with either DMSO (97.6% proliferation)
or ATRA (96.7% proliferation; top, Figure 5b).
However, T cells from brain-injured mice showed a
diminished capacity for proliferation when cultured
with DMSO (64.9% proliferation) or ATRA (81.1%
proliferation; bottom, Figure 5b).

Discussion
TBI may potentiate peripheral inflammatory pain
through unregulated systemic inflammation
We show that TBI potentiated carrageenan-induced
mechanical hyperalgesia. Our results are the ﬁrst to
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Figure 5. TBI alters regulatory T cell development. CD4þ T cells from mesenteric lymph nodes of brain-injured (n ¼ 4) or sham mice
(n ¼ 4) were cultured in media containing DMSO or ATRA, a Treg stimulating factor. (a) T cells were sorted by flow cytometry for
traditional markers of T cell activation (CD25) and Treg differentiation (Foxp3). DMSO-treated T cells exhibited a nominal percentage of
CD25hi/Foxp3hi Tregs (values displayed in upper right quadrant of each panel). In T cells from sham mice, ATRA stimulation elicited an
increase in Treg differentiation that was not observed in brain-injured mice. (b) T cell proliferation was assayed using CFSE assay indicating a
reduction in proliferation capacity among T cells from brain-injured mice regardless of media additive (percent of population composed of
proliferated cells indicated).
TBI: traumatic brain injury; DMSO: dimethyl sulfoxide; ATRA: all-trans retinoic acid; CFSE: carboxyfluorescein succinimidyl ester.

advance the idea that TBI-associated increases in inﬂammation and inﬂammatory mediators contribute to the
potentiation of hyperalgesia following a peripheral
immune challenge.13 TBI activates microglia and astrocytes.36,37 Microglia are resident immune cells of the
brain which respond to pathological insult and tissue
injury. Following TBI, microglia respond to insult by
proliferating and undergoing a phenotypic shift toward
‘‘activation.’’ Activated microglia synthesize and release
cytokines into the extracellular environment which
have a dual role as inﬂammation mediators and pronociceptive mediators.9 Similarly, following a change
in the environment such as mechanical injury associated with TBI, astrocytes shift to a reactive phenotype and undergo hypertrophy. In the current study,
we demonstrate brain injury-induced activation of both
cortical microglia and astrocytes at seven days postinjury. We have previously shown cortical glia activation
in the mouse as early as 6 h postinjury33 supporting
rapid glia activation that persists through seven days
postinjury. While this is not a novel ﬁnding, it is an
important conﬁrmation of central inﬂammation at
seven days postinjury in the same animals presenting

with hyperalgesia following a peripheral immune
challenge.
In the context of experimental and clinical brain
injury, glial activation serves as a hallmark of the pathology. Glial activation may lead the injury and repair
processes or simply serve as a marker of pathology. In
fact, the peripheral increase in circulating GFAP is a
leading ﬂuid-based biomarker for detecting brain
injury,38 further demonstrating glial activation and
transfer of molecules between central and peripheral
compartments. Days following TBI, immune cross talk
can likely augment central and peripheral inﬂammation,
which can further contribute to increased sensitivity to
secondary challenges including subsequent injuries, stressors, and infections.39 Following diﬀuse TBI in mice,
microglia are primed, to a heightened state of activation,
and this brain-injury-induced inﬂammatory response has
been shown to result in an augmented response to a subsequent peripheral immune challenge one month postinjury.39 These mice were subjected to mFPI and
lipopolysaccharide (LPS) injection (30 days post-FPI),
which demonstrated increased depression-like behavior
in comparison to mice subjected to either FPI or LPS
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alone.39 Similarly, in the current study, we show mFPI in
mice activated microglia which may prime them for a
secondary challenge (carrageenan injection).

Leakage of cytokines and chemokines from the CNS
to the periphery may contribute to TBI potentiation of
peripheral inflammatory pain
Under normal conditions, the pain pathway is activated
to induce an active and protective response to help prevent further tissue damage.8 However, when injury and
inﬂammation are prolonged, the ongoing excitation of
primary nociceptive neurons can lead to chronic and
maladaptive pain.11 Previous studies have shown
in vivo injections of IL-1b, IL-6, or TNF-a induce an
active inﬂammatory event similar to a carrageenan challenge and result in hyperalgesia.40–42 More direct, intraplantar injection of IL-6 into naı̈ve animals has been
shown to induce mechanical hyperalgesia.43
Following brain injury, an inﬂammatory response is
generated by activated glia, which leads to a proinﬂammatory cytokine response. The resultant inﬂammatory
response is further ampliﬁed by migrating blood cells.13
Proinﬂammatory cytokines excite nociceptive ﬁbers and
increase neural sensitivity.11,17,44–46 Thus, cytokines are
not merely inﬂammatory mediators, but are also neuromodulators, by having direct excitatory actions on peripheral nociceptive neurons. In the current study, diﬀuse
TBI increased cortical and serum levels of cytokine IL-6
and chemokine CXCL1. Based on these observations, we
suggest that diﬀuse TBI induced a CNS inﬂammatory
response, which transitioned rapidly into secreted inﬂammatory cytokines found in serum, which could potentiate
inﬂammatory pain (Figure 1). Thus, TBI may lead to an
acute increase in proinﬂammatory molecules in the brain
that then leak to the periphery, thereby increasing levels
in the serum. The ensuing cytokine signaling then
potentiates hyperalgesia, as observed.
It is important to note that in the absence of the peripheral inﬂammation induced by the carrageenan injection, we observed no change in sensory thresholds in
mFPI-injured mice compared with uninjured shams at
seven days postinjury. This diﬀers from a recent study
where TBI induced by lateral ﬂuid percussion (later ﬂuid
percussion injury [lFPI]) led to sustained nociceptive sensitization for four days postinjury, without provocation.47 lFPI is characterized by both focal and diﬀuse
injury in which mechanical damage results in cell death
and the development of a cavitation.48,49 It is possible the
disruption of the dura and formation of a cavitation
extensively disrupts the BBB and initiates a more profound peripheral inﬂammatory response in the ﬁrst week
postinjury compared with mFPI in the mouse.48 Further
investigation is necessary to compare peripheral
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inﬂammation following experimental mFPI and lFPI.
In the present case of mFPI, a widespread diﬀuse brain
injury may prime the immune response; whereby, a
second inﬂammatory challenge may be needed to
potentiate peripheral inﬂammatory pain. In contrast,
focal injury may substantially increase peripheral inﬂammation, thus potentiating peripheral inﬂammatory pain
in the absence of a second inﬂammatory challenge.

Suppressed proliferation and differentiation of Tregs
may contribute to pain and dysregulated inflammation
following TBI
Our results indicate that MLNs from brain-injured mice
cultured with the Treg stimulating factor ATRA failed to
diﬀerentiate into Tregs. Although ATRA enhances
the TGFb-dependent anti-inﬂammatory Treg cell diﬀerentiation and stability,50,51 addition of ATRA in a proinﬂammatory context (e.g. IL-15-enriched intestinal
mucosa) may promote the inﬂammatory response
instead.52 Further studies will be necessary to elucidate
whether TBI may favor a particular immunological
environment in MLNs. Treg diﬀerentiation is vital for
controlling adaptive and innate immune responses and
may also attenuate neuropathic pain. Previous studies
have shown neuropathic pain induced by experimental
autoimmune neuritis can be attenuated by increasing
Tregs,12 thus the inability of T cells to diﬀerentiate into
Tregs could contribute to hyperalgesia following experimental TBI.
Our results also indicated that CD4þ MLN T cells
from brain-injured mice had suppressed proliferation
compared to MLN T cells from sham mice. It has been
shown CD4þ T cells from postseptic mice isolated and
assayed for ex vivo proliferation following acute
inﬂammation demonstrated deﬁciencies in proliferative
capacity.53,54 Similarly, thermal injury resulted in
impaired T cell proliferation in mice.55 Clinically,
18–72 h after severe TBI, the number of circulating T
cells, T-helper cells, and Tregs were reduced.56,57
Hence, an inﬂammatory challenge, or injury, could
lead to cytokine dysregulation, which impairs lymphocyte proliferation, suppresses T cell activation, and alters
cell-mediated responses.53–55 In the current study, we
show increased cytokine production following diﬀuse
TBI. The resulting systemic proinﬂammatory environment post-TBI may prime immune cells for a rapid
and eﬃcient response against any challenge that may
momentarily put a vulnerable, vital organ such as the
brain at high risk. Under these conditions, disruption
of the Treg cell homeostasis post-TBI, as seen in this
study, may support a strong immune response against
potential harmful agents. However, it may also prevent
the protective role of Tregs in controlling the
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exacerbated inﬂammatory reaction to an otherwise weak
secondary challenge. Further studies are necessary to
elucidate the contribution of brain injury on T cell activation and fate decisions.

Conclusion
In summary, diﬀuse brain injury led to hyperalgesia following a carrageenan injection in the paw, potentially
caused by increased glial activation, central and peripheral increases of inﬂammatory mediators, and dysregulation of Treg induction. A potential limitation of the
current study is the number of animals used in each
group, thus, future experiments are needed to elucidate
directly the role of Tregs in chronic pain after TBI.
Further experiments investigating mechanical pain
thresholds post-TBI in other inﬂammatory pain models
such as formalin are of interest but beyond the scope of
this experiment. Future experiments are needed to comprehensively investigate inﬂammatory pain models following experimental diﬀuse brain injury. Targeting
posttraumatic inﬂammation may reduce secondary
injury and improve patient outcome, thus investigation
into Treg therapy may be a potential therapeutic target
for diﬀuse brain injury. Furthermore, research is needed
to reveal the impact of TBI-induced cytokines and chemokines in the brain on primary aﬀerent nociceptors.
Although current studies focus on how glial activation
in the spinal cord modulate pain pathways, a lack of
studies evaluating how glial activation following brain
injury contributes to pain warrants further investigation.
Acknowledgments
The authors thank Greg Bauman and Jennifer Strange for technical assistance.

Authors’ contributions
RKR and JLH carried out the mouse surgeries and injuries,
tissue collection, immunohistochemical staining, and data analyses. GIE, RKR, BKT, JL, and FM made substantial contributions to the conception and study design and GIE and FM
contributed to peripheral immune data collection and analyses.
GIE and GFC carried out the von Frey ﬁlament test. ADB and
LVE carried out the cytokine measurements in the cortex and
serum and analyzed these data. BKT made substantial contributions to the interpretation of the data and made critical revisions to the intellectual content of the manuscript. RKR, GIE,
and JL drafted the manuscript and all authors provided revisions and approved the ﬁnal version. RKR and GIE contributed equally to the manuscript.

Declaration of Conflicting Interests
The author(s) declared no potential conﬂicts of interest with
respect to the research, authorship, and/or publication of this
article.

Molecular Pain 0(0)
Funding
The author(s) disclosed receipt of the following ﬁnancial support for the research, authorship, and/or publication of this
article: This work is supported by NIH grants K02 DA19656
and R01 DA037621 (BKT) and R01 NS065052 (JL). Dr. Rowe
is funded by a Bisgrove Scholar Award from Science
Foundation Arizona. Mr. Harrison was partially supported
by the Diane and Bruce Halle Foundation and NIH F31
NS09092. Flow cytometry was carried out at the University
of Kentucky Flow Cytometry and Cell Sorting Core Facility,
which is supported in part by the Oﬃce of the Vice President
for Research, the Markey Cancer Center and a grant from the
NIH Shared Instrument Program (S10 RR026827).

References
1. Lahz S and Bryant RA. Incidence of chronic pain following traumatic brain injury. Arch Phys Med Rehabil 1996;
77: 889–891.
2. Nampiaparampil DE. Prevalence of chronic pain after
traumatic brain injury: a systematic review. JAMA 2008;
300: 711–719.
3. Bosco MA, Murphy JL and Clark ME. Chronic pain and
traumatic brain injury in OEF/OIF service members and
Veterans. Headache 2013; 53: 1518–1522.
4. Hoffman JM, Pagulayan KF, Zawaideh N, et al.
Understanding pain after traumatic brain injury: impact
on community participation. Am J Phys Med Rehabil
2007; 86: 962–969.
5. Gironda RJ, Clark ME, Massengale JP, et al. Pain among
veterans of operations enduring freedom and Iraqi freedom. Pain Med 2006; 7: 339–343.
6. Feliciano DP, Sahbaie P, Shi X, et al. Nociceptive
sensitization and BDNF up-regulation in a rat model of
traumatic brain injury. Neurosci Lett 2014; 583: 55–59.
7. Elliott MB, Oshinsky ML, Amenta PS, et al. Nociceptive
neuropeptide increases and periorbital allodynia in a model
of traumatic brain injury. Headache 2012; 52: 966–984.
8. Millan MJ. The induction of pain: an integrative review.
Prog Neurobiol 1999; 57: 1–164.
9. Old EA, Clark AK and Malcangio M. The role of glia in
the spinal cord in neuropathic and inflammatory pain.
Handb Exp Pharmacol 2015; 227: 145–170.
10. Ellis A and Bennett DL. Neuroinflammation and the generation of neuropathic pain. Br J Anaesth 2013; 111: 26–37.
11. Milligan ED and Watkins LR. Pathological and protective
roles of glia in chronic pain. Nat Rev Neurosci 2009; 10:
23–36.
12. Austin PJ, Kim CF, Perera CJ, et al. Regulatory T cells
attenuate neuropathic pain following peripheral nerve
injury and experimental autoimmune neuritis. Pain 2012;
153: 1916–1931.
13. Sommer C and Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms
in inflammatory and neuropathic hyperalgesia. Neurosci
Lett 2004; 361: 184–187.
14. Ziebell JM and Morganti-Kossmann MC. Involvement of
pro- and anti-inflammatory cytokines and chemokines in

Rowe et al.

15.

16.

17.

18.
19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

the pathophysiology of traumatic brain injury.
Neurotherapeutics 2010; 7: 22–30.
Das M, Mohapatra S and Mohapatra SS. New perspectives on central and peripheral immune responses to acute
traumatic brain injury. J Neuroinflammation 2012; 9: 236.
Lenzlinger PM, Morganti-Kossmann MC, Laurer HL,
et al. The duality of the inflammatory response to traumatic brain injury. Mol Neurobiol 2001; 24: 169–181.
Beggs S and Salter MW. The known knowns of microglianeuronal signalling in neuropathic pain. Neurosci Lett
2013; 557(Pt A): 37–42.
Sandkuhler J. Models and mechanisms of hyperalgesia and
allodynia. Physiol Rev 2009; 89: 707–758.
Witcher KG, Eiferman DS and Godbout JP. Priming the
inflammatory pump of the CNS after traumatic brain
injury. Trends Neurosci 2015; 38: 609–620.
Ellis GI, Reneer MC, Velez-Ortega AC, et al. Generation
of induced regulatory T cells from primary human naive
and memory T cells. J Vis Exp 2012; 62: 3738.
Wing K and Sakaguchi S. Regulatory T cells exert checks
and balances on self tolerance and autoimmunity. Nature
Immunol 2010; 11: 7–13.
Maloy KJ, Salaun L, Cahill R, et al. CD4þCD25þ T(R)
cells suppress innate immune pathology through cytokinedependent mechanisms. J Exp Med 2003; 197: 111–119.
Murphy TJ, Ni Choileain N, Zang Y, et al.
CD4 þ CD25 þ regulatory T cells control innate immune
reactivity after injury. J Immunol 2005; 174: 2957–2963.
Josefowicz SZ, Niec RE, Kim HY, et al. Extrathymically
generated regulatory T cells control mucosal TH2 inflammation. Nature 2012; 482: 395–399.
Josefowicz SZ, Lu LF and Rudensky AY. Regulatory T
cells: mechanisms of differentiation and function. Annu
Rev Immunol 2012; 30: 531–564.
Huang H, Ma Y, Dawicki W, et al. Comparison of induced
versus natural regulatory T cells of the same TCR specificity for induction of tolerance to an environmental antigen.
J Immunol 2013; 191: 1136–1143.
Lifshitz J. Fluid percussion injury model. In: Chen J, Xu
XC, Xu X-M, et al (eds) Animal models of acute neurological injuries. Totowa, NJ: The Humana Press Inc.,
2008, pp.369–384.
Hosseini AH and Lifshitz J. Brain injury forces of moderate magnitude elicit the fencing response. Med Sci Sports
Exerc 2009; 41: 1687–1697.
Bachstetter AD, Xing B, de Almeida L, et al. Microglial
p38alpha MAPK is a key regulator of proinflammatory
cytokine up-regulation induced by toll-like receptor
(TLR)
ligands
or
beta-amyloid
(Abeta).
J Neuroinflammation 2011; 8: 79.
Bachstetter AD, Rowe RK, Kaneko M, et al. The
p38alpha MAPK regulates microglial responsiveness to
diffuse traumatic brain injury. J Neurosci 2013; 33:
6143–6153.
Corder G, Doolen S, Donahue RR, et al. Constitutive muopioid receptor activity leads to long-term endogenous
analgesia and dependence. Science 2013; 341: 1394–1399.
Posadas I, Bucci M, Roviezzo F, et al. Carrageenaninduced mouse paw oedema is biphasic, age-weight

11

33.

34.

35.

36.

37.

38.

39.

40.

41.

42.

43.

44.
45.

46.

47.

48.

dependent and displays differential nitric oxide cyclooxygenase-2 expression. Br J Pharmacol 2004; 142: 331–338.
Rowe RK, Striz M, Bachstetter AD, et al. Diffuse brain
injury induces acute post-traumatic sleep. PLoS One 2014;
9: e82507.
Harrison JL, Rowe RK, Ellis TW, et al. Resolvins AT-D1
and E1 differentially impact functional outcome, post-traumatic sleep, and microglial activation following diffuse
brain injury in the mouse. Brain Behav Immun 2015; 47:
131–140.
Schmidt RH and Grady MS. Regional patterns of bloodbrain barrier breakdown following central and lateral fluid
percussion injury in rodents. J Neurotrauma 1993; 10:
415–430.
Ziebell JM, Taylor SE, Cao T, et al. Rod microglia: elongation, alignment, and coupling to form trains across the
somatosensory cortex after experimental diffuse brain
injury. J Neuroinflammation 2012; 9: 247.
Cao T, Thomas TC, Ziebell JM, et al. Morphological and
genetic activation of microglia after diffuse traumatic brain
injury in the rat. Neuroscience 2012; 225: 65–75.
Mondello S, Papa L, Buki A, et al. Neuronal and glial
markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study. Crit Care 2011; 15:
R156.
Fenn AM, Gensel JC, Huang Y, et al. Immune activation
promotes depression 1 month after diffuse brain injury: a
role for primed microglia. Biol Psychiatry 2014; 76:
575–584.
Reichling DB and Levine JD. Critical role of nociceptor
plasticity in chronic pain. Trends Neurosci 2009; 32:
611–618.
Schafers M, Svensson CI, Sommer C, et al. Tumor necrosis
factor-alpha induces mechanical allodynia after spinal
nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 2003; 23: 2517–2521.
Zelenka M, Schafers M and Sommer C. Intraneural injection of interleukin-1beta and tumor necrosis factor-alpha
into rat sciatic nerve at physiological doses induces signs of
neuropathic pain. Pain 2005; 116: 257–263.
Cunha FQ and Tamashiro WM. Tumour necrosis factoralpha and interleukin-8 inhibit neutrophil migration
in vitro and in vivo. Mediators Inflamm 1992; 1: 397–401.
Basbaum AI, Bautista DM, Scherrer G, et al. Cellular and
molecular mechanisms of pain. Cell 2009; 139: 267–284.
DeLeo JA and Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain
2001; 90: 1–6.
Myers RR, Campana WM and Shubayev VI. The role of
neuroinflammation in neuropathic pain: mechanisms and
therapeutic targets. Drug Discov Today 2006; 11: 8–20.
Feliciano DP, Sahbaie P, Shi X, et al. Nociceptive sensitization and BDNF up-regulation in a rat model of traumatic brain injury. Neurosci Lett 2014; 583: 55–59.
Alder J, Fujioka W, Lifshitz J, et al. Lateral fluid percussion: model of traumatic brain injury in mice. J Vis Exp
2011; 54: 3063.

12
49. Eakin K, Rowe RK and Lifshitz J. Modeling fluid percussion injury: relevance to human traumatic brain injury.
In: Kobeissy FHP (ed.) Brain neurotrauma: molecular,
neuropsychological, and rehabilitation aspects. Boca
Raton, FL: Frontiers in Neuroengineering, 2015, pp.1–27.
50. Hall JA, Cannons JL, Grainger JR, et al. Essential role for
retinoic acid in the promotion of CD4(þ) T cell effector
responses via retinoic acid receptor alpha. Immunity 2011;
34: 435–447.
51. Liu ZM, Wang KP, Ma J, et al. The role of all-trans retinoic acid in the biology of Foxp3 regulatory T cells. Cell
Mol Immunol 2015; 12: 553–557.
52. DePaolo RW, Abadie V, Tang F, et al. Co-adjuvant effects
of retinoic acid and IL-15 induce inflammatory immunity
to dietary antigens. Nature 2011; 471: 220–224.
53. Carson WFt, Cavassani KA, Ito T, et al. Impaired CD4þ
T-cell proliferation and effector function correlates with

Molecular Pain 0(0)

54.

55.

56.

57.

repressive histone methylation events in a mouse model
of severe sepsis. Eur J Immunol 2010; 40: 998–1010.
Napolitano LM and Campbell C. Polymicrobial sepsis following trauma inhibits interleukin-10 secretion and
lymphocyte proliferation. J Trauma 1995; 39: 104–110;
discussion 10-1.
Napolitano LM and Campbell C. Nitric oxide inhibition
normalizes splenocyte interleukin-10 synthesis in murine
thermal injury. Arch Surg 1994; 129: 1276–1282;
discussion 82-3.
Wolach B, Sazbon L, Gavrieli R, et al. Early immunological defects in comatose patients after acute brain
injury. J Neurosurg 2001; 94: 706–711.
Dziedzic T, Slowik A and Szczudlik A. Nosocomial infections and immunity: lesson from brain-injured patients.
Crit Care 2004; 8: 266–270.

